Functional neuroimaging in the diagnosis of patients with parkinsonism: Update and recommendations for clinical use

被引：15

作者：

Arbizu, J. ^{[1
]}

Luquin, M. R. ^{[2
]}

Abella, J. ^{[3
]}

de la Fuente-Fernandez, R. ^{[3
]}

Fernandez-Torron, R. ^{[4
]}

Garcia-Solis, D. ^{[5
]}

Garrastachu, P. ^{[6
]}

Jimenez-Hoyuela, J. M. ^{[7
]}

Llaneza, M. ^{[3
]}

Lomena, F. ^{[8
]}

Lorenzo-Bosquet, C. ^{[9
]}

Marti, M. J. ^{[10
]}

Martinez-Castrillo, J. C. ^{[11
]}

Mir, P. ^{[12
]}

Mitjavila, M. ^{[13
]}

Ruiz-Martinez, J. ^{[14
]}

Vela, L. ^{[15
]}

机构：

[1] Univ Navarra Clin, Nucl Med Serv, Grp Trabajo Neuroimagen SEMNIM, Pamplona, Spain

[2] Univ Navarra Clin, Dept Neurol, Grp Trastornos Movimiento SEN, Pamplona, Spain

[3] Hosp A, Serv Neurol, Marcide, Ferrol, Spain

[4] CIBERNED, Inst Invest Biodonostia, Area Neurociencias, Serv Neurol,Hosp Univ Donostia, San Sebastian, Spain

[5] Hosp Univ Virgen Rocio, Ctr Invest Biomed Red Enfermedades Neurodegenerat, UDIM, Nucl Med Serv, Seville, Spain

[6] Hosp San Pedro, Nucl Med Serv, CIBIR, Logrono, Spain

[7] Hosp Univ Virgen Victoria, Nucl Med Serv, Malaga, Spain

[8] Hosp Clin Barcelona, Nucl Med Serv, Barcelona, Spain

[9] Hosp Valle De Hebron, Nucl Med Serv, CETIR ERESA, Unitat Teknon, Barcelona, Spain

[10] Hosp Clin Barcelona, CIBERNET, Unidad Parkinson Trastornos Movimiento, Serv Neurol,ICN, Barcelona, Spain

[11] Hosp Ramon & Cajal, Serv Neurol, E-28034 Madrid, Spain

[12] Hosp Univ Virgen Rocio, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Inst Biomed Sevilla IBiS, Unidad Trastornos Movimiento,Serv Neurol & Neurof, Seville, Spain

[13] Hosp Univ Puerta Hierro, Nucl Med Serv, Madrid, Spain

[14] Hosp Univ Donostia, CIBERNED, Unidad Parkinson & Otros Trastornos Movimiento, Serv Neurol,Inst Salud Carlos III, San Sebastian, Guipuzcoa, Spain

[15] Hosp Univ Fdn Alcorcon, Serv Neurol, Alcorcon, Spain

来源：

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR | 2014年 / 33卷 / 04期

关键词：

Parkinson's disease; Parkinsonism; Scintigraphy; SPECT; PET; Differential diagnosis; MULTIPLE SYSTEM ATROPHY; CEREBRAL GLUCOSE-METABOLISM; EANM PROCEDURE GUIDELINES; DRUG-INDUCED PARKINSONISM; DIFFERENTIAL-DIAGNOSIS; VASCULAR PARKINSONISM; CORTICOBASAL DEGENERATION; REGIONAL SELECTIVITY; LRRK2; MUTATIONS; VERSION;

D O I：

10.1016/j.remn.2014.02.001

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Functional Neuroimaging has been traditionally used in research for patients with different parkinsonian syndromes. However, the emergence of commercial radiotracers together with the availability of single photon emission computed tomography (SPECT) and, more recently, positron emission tomography (PET) have made them available for clinical practice. Particularly, the development of clinical evidence achieved by functional neuroimaging techniques over the past two decades have motivated a progressive inclusion of several biomarkers in the clinical diagnostic criteria for neurodegenerative diseases that occur with parkinsonism. However, the wide range of radiotracers designed to assess the involvement of different pathways in the neurodegenerative process underlying parkinsonian syndromes (dopaminergic nigrostriatal pathway integrity, basal ganglia and cortical neuronal activity, myocardial sympathetic innervation), and the different neuroimaging techniques currently available (scintigraphy, SPECT and PET), have generated some controversy concerning the best neuroimaging test indicated for the differential diagnosis of parkinsonism. In this article, a panel of nuclear medicine and neurology experts has evaluated the functional neuroimaging techniques emphazising practical considerations related to the diagnosis of patients with uncertain origin parkinsonism and the assessment of Parkinson's disease progression. (C) 2014 Elsevier Espana, S.L. and SEMNIM. All rights reserved.

引用

页码：215 / 226

页数：12

共 54 条

[1] PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation [J].